Halozyme Therapeutics (NASDAQ:HALO) Stock Sale Disclosed by Rep. Gilbert Ray Cisneros, Jr.

Key Points

• Rep. Gilbert Ray Cisneros Jr. sold $1,001–$15,000 of Halozyme Therapeutics stock on September 29, according to a filing disclosed October 12. He also reported multiple purchases and sales across other companies.
• Halozyme reported strong quarterly results, with EPS of $2.28 versus the $1.79 consensus and revenue up 47.7% year over year to $481 million. The company issued fiscal 2026 EPS guidance of $8.65–$9.00.
• Analysts maintain a generally positive view, with nine Buy ratings and a “Moderate Buy” consensus, while recent insider sales totaled $13.5 million over three months. Institutional investors own approximately 97.8% of the company.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO). In a filing disclosed on October 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Halozyme Therapeutics stock on September 29th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 - $50,000 in shares of Benchmark Electronics NYSE: BHE on 10/1/2026.
• Sold $1,001 - $15,000 in shares of Oxford Industries NYSE: OXM on 9/29/2026.
• Sold $1,001 - $15,000 in shares of Semtech NASDAQ: SMTC on 9/29/2026.
• Sold $15,001 - $50,000 in shares of ITT NYSE: ITT on 9/29/2026.
• Sold $1,001 - $15,000 in shares of BridgeBio Pharma NASDAQ: BBIO on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Tandem Diabetes Care NASDAQ: TNDM on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Cytokinetics NASDAQ: CYTK on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Ultragenyx Pharmaceutical NASDAQ: RARE on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of YETI NYSE: YETI on 9/29/2026.
• Sold $1,001 - $15,000 in shares of AtriCure NASDAQ: ATRC on 9/29/2026.

Halozyme Therapeutics Stock Down 1.3%

Shares of NASDAQ HALO opened at $109.62 on Wednesday. Halozyme Therapeutics, Inc. has a 12-month low of $61.22 and a 12-month high of $116.85. The firm's 50-day simple moving average is $107.30 and its 200 day simple moving average is $83.87. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The company has a market cap of $12.44 billion, a price-to-earnings ratio of 22.53, a price-to-earnings-growth ratio of 0.42 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping analysts' consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The company had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. During the same period in the previous year, the firm posted $1.54 earnings per share. The company's revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, research analysts expect that Halozyme Therapeutics, Inc. will post 8.25 earnings per share for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the firm's stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $107.43, for a total value of $2,148,600.00. Following the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at $82,482,605.40. This trade represents a 2.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew Posard sold 18,996 shares of Halozyme Therapeutics stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $107.74, for a total value of $2,046,629.04. Following the sale, the director directly owned 58,839 shares of the company's stock, valued at approximately $6,339,313.86. This trade represents a 24.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 125,852 shares of company stock worth $13,538,046 in the last three months. Insiders own 2.50% of the company's stock.

Analyst Ratings Changes

Several research analysts recently weighed in on HALO shares. Citigroup restated a "market outperform" rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. JPMorgan Chase & Co. increased their price objective on Halozyme Therapeutics from $70.00 to $78.00 and gave the company a "neutral" rating in a research report on Thursday, October 8th. Leerink Partners raised Halozyme Therapeutics from a "market perform" rating to an "outperform" rating and lifted their target price for the company from $83.00 to $110.00 in a research note on Friday, August 7th. HC Wainwright boosted their target price on Halozyme Therapeutics from $115.00 to $130.00 and gave the stock a "buy" rating in a research report on Wednesday, October 7th. Finally, Citizens Jmp boosted their target price on Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a "market outperform" rating in a research report on Friday, August 7th. Nine research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $96.50.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of HALO. Signal Advisors Wealth LLC bought a new position in Halozyme Therapeutics in the third quarter valued at approximately $850,000. B. Riley Wealth Advisors Inc. bought a new stake in shares of Halozyme Therapeutics during the 3rd quarter valued at $232,000. Cooper Investors PTY Ltd. raised its position in shares of Halozyme Therapeutics by 19.8% during the 3rd quarter. Cooper Investors PTY Ltd. now owns 65,933 shares of the biopharmaceutical company's stock valued at $7,279,000 after acquiring an additional 10,910 shares during the last quarter. NorthCrest Asset Manangement LLC lifted its stake in shares of Halozyme Therapeutics by 27.7% in the 3rd quarter. NorthCrest Asset Manangement LLC now owns 57,661 shares of the biopharmaceutical company's stock valued at $6,333,000 after purchasing an additional 12,511 shares during the period. Finally, GK Wealth Management LLC acquired a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at $178,000. 97.79% of the stock is owned by institutional investors.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company's primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.